NEW YORK, Nov. 4, 2016 /PRNewswire/ -- Pomerantz LLP
is investigating claims on behalf of investors of Teva
Pharmaceuticals Industries Limited ("Teva" or the "Company") (NYSE:
TEVA) (ISIN: US8816242098). Investors are advised to contact
Robert S. Willoughby at
rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Teva and certain of its
officers and/or directors have violated the federal securities
laws
[Click here to join a class action]
On November 3, 2016, media outlets
reported that United States
prosecutors may file criminal charges by the end of 2016 against
Teva and several other pharmaceutical companies for unlawfully
colluding to fix generic drug prices.
On this news, Teva's share price fell $4.13, or 9.53%, to close at $39.20 on November 3,
2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-teva-pharmaceuticals-industries-limited--teva-300357720.html
SOURCE Pomerantz LLP